Compare Cytokinetics Inc (CYTK) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vanguard Mega Cap Growth ETF — how do they compare? Cytokinetics Inc trades at $81.44 (market cap $11.12B), while Vanguard Mega Cap Growth ETF trades at $88.96. Which is the better fit depends on your goals.
| CYTK | MGK | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $87.26 | $92.06 |
52-Week Low | $33.23 | $70.70 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
MGK (Vanguard Mega Cap Growth ETF) trades at $87.69, down 1.54% today amid a bearish technical signal. The ETF maintains a concentrated portfolio of 69 large-cap growth stocks with heavy technology exposure and a low 0.05% expense ratio. Recent developments include a 1:5 stock split effective April 21, 2026, and potential addition of SpaceX following its recent IPO.
The ETF's concentrated mega-cap growth strategy offers strong long-term return potential but carries sector concentration risk. Technical indicators suggest near-term consolidation while fundamental strength in technology holdings supports the bullish long-term thesis. Investors should weigh the ETF's historical outperformance against its vulnerability to tech sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
